Angiogenesis in Waldenström's macroglobulinemia.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Angiogenesis is a critical process in the progression of hematological malignancies.
• In Waldenström's macroglobulinemia (WM), increased bone marrow microvessel density is observed in 30%-40% of patients, but its impact on survival is unclear.
• Elevated levels of angiogenic cytokines like vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are noted in WM and IgM-monoclonal gammopathy of undetermined significance (MGUS).

Purpose of the Study:

• To review the available literature up to November 2008 on the role of angiogenesis in Waldenström's macroglobulinemia (WM).
• To correlate angiogenic factors and cellular players with the clinical and laboratory features of WM.
• To assess the significance of angiogenesis in the disease biology of WM.

Main Methods:

• Literature search for studies investigating angiogenesis in Waldenström's macroglobulinemia (WM) and related conditions.
• Analysis of data on microvessel density, angiogenic cytokines, and cellular components in WM patients.
• Correlation of angiogenic markers with disease activity and clinical manifestations.

Main Results:

• While bone marrow microvessel density is increased in a subset of WM patients, it does not appear to impact survival.
• Serum levels of angiogenin, VEGF, and bFGF are elevated in WM and IgM-MGUS.
• The angiopoietin-1/angiopoietin-2 ratio is reduced in WM but not IgM-MGUS, and correlates with disease activity and clinical features. Macrophage and mast cell chemoattractants are also elevated, and these cells contribute to angiogenesis in WM.

Conclusions:

• Angiogenesis plays a role in the biology of Waldenström's macroglobulinemia (WM).
• Specific angiogenic factors and cellular components are altered in WM and correlate with disease characteristics.
• Further research into targeting angiogenesis may offer therapeutic potential for WM.